Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya3294410.26442/00403660.2018.12.000018Editorial articleПередовая статьяReview ArticleBiomarkers of inflammatory bowel disease activityБиомаркеры активности воспалительных заболеваний кишечникаFadeevaN AФадееваНина Александровна

к.м.н., с.н.с. отд-ния воспалительных заболеваний кишечника

KorneevaI AКорнееваИрина Алексеевна

клинический ординатор отд-ния лечения воспалительных заболеваний кишечника

KnyazevO VКнязевОлег Владимирович

д.м.н., зав. отд-нием лечения воспалительных заболеваний кишечника

ParfenovA IПарфеновАсфольд Иванович

д.м.н., проф., зав. отд. патологии кишечника

asfold@mail.ruA.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of MoscowГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы151220189012VOL 90, NO12 (2018)ТОМ 90, №12 (2018)10711111042020Copyright ©; 2018, Consilium MedicumCopyright ©; 2018, ООО "Консилиум Медикум"2018Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/32944

The review presents data on calprotectin, lactoferrin, leukocytes labeled with isotope indium 111In, calgranulin C and pyruvate kinase type M2 - highly sensitive biomarkers to assess the severity of intestinal inflammation. Their importance in diagnostics, determination of treatment efficiency, including as predictors of recurrence of ulcerative colitis and Crohn's disease is shown.

В обзоре представлены сведения о кальпротектине, лактоферрине, лейкоцитах, меченных изотопом индия 111In, кальгранулине С и пируваткиназе типа М2 - высокочувствительных биомаркерах, позволяющих оценить степень тяжести воспаления кишечника. Показано их значение в диагностике, определении эффективности лечения, в том числе в качестве предикторов рецидивов язвенного колита и болезни Крона.

Crohn's diseaseinflammatory bowel diseaseC calgranulinM2 pyruvate kinaseirritable bowel syndromefecal calprotectinulcerative colitisболезнь Кронавоспалительные заболевания кишечникакальгранулин Спируваткиназа типа М2синдром раздраженного кишечникафекальный кальпротектинязвенный колитD'Haens G, Feagan B, Colombel J.F, Sandborn W.J, et al. Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. Gastroenterology. 2012;143(6):1461-9. doi: 10.1053/j.gastro.2012.09.031Lobaton T, Rodriguez-Moranta F, Rodriguez-Alonso L, Guardiola J. Fecal calprotectin in the diagnosis of inflammatory bowel diseases. Gastroenterol Hepatol. 2013;36(6):400-6. doi: 10.1016/j.gastrohep.2012.10.008Manz M, Burri E, Rothen C, Tchanguizi N, Niederberger C, Rossi L, Beglinger C, Lehmann F.S. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC Gastroenterol. 2012;12:5. doi: 10.1186/1471-230X-12-5Парфенов А.И., Крумс Л.М. Энтеропатия с потерей белка. Терапевтический архив. 2017;89(2):4-9 doi: 10,17116/terarkh20178924-9Sherwood R.A. Faecal markers of gastrointestinal inflammation. J Clin Pathol. 2012;65(11):981-5. doi: 10.1136/jclinpath-2012-200901Boschetti G, Laidet M, Moussata D, et al. Levels of fecal calprotectin are associated with the severity of postoperative endoscopic recurrence in asymptomatic patients with Crohn's disease. Am J Gastroenterol. 2015;110(6):865-72. doi: 10.1038/ajg.2015.30Burri E, Beglinger C, von Feiten S, Lehmann F.S. Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis. Dig Dis Sci. 2015;60(2):485-91. doi: 10.1007/s10620-014-3383-0Labaere D, Smismans A, van Olmen A, et al. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. Unit Eur Gastroenterol J. 2014;2(1):30-7. doi: 10.1177/2050640613518201Осипенко М.Ф., Ливзан М.А., Скалинская М.И., Лялюкова Е.А. Концентрация фекального кальпротектина в дифференциальной диагностике заболеваний кишечника. Терапевтический архив. 2015;87(2):30-3. doi: 10.17116/terarkh201587230-33Lehmann F.S, Burri E, Beglinger C. The role and utility of faecal markers in inflammatory bowel disease. Therap Adv Gastroenterol. 2015;8(1):23-36. doi: 10.1177/1756283X14553384Molander P, Bjorkesten C, Mustonen H, et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis. 2012;18(11):2011-7. doi: 10.1002/ibd.22863Coorevits L, Baert F.J, Vanpoucke H.J. Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method. Clin Chem Lab Med. 2013;51(4):825-31. doi: 10.1515/cclm-2012-0386Pavlidis P, Chedgy F.J, Tibbie. Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care. Scand J Gastoenterol. 2013;48(9):1048-54. doi: 10.3109/00365521.2013.816771Sithambaram S, Hilmi I, Goh K.L. The Diagnostic Accuracy of the M2 Pyruvate Kinase Quick Stool Test - A Rapid Office Based Assay Test for the Detection of Colorectal Cancer. PLoS One. 2015;10(7):e0131616. doi: 10.1371/journal.pone.0131616Nielsen H.L, Engberg J, Ejlertsen T, Nielsen H. Evaluation of fecal calprotectin in Campylobacter concisus and Campylobacter jejuni/coli gastroenteritis. Scаnd J Gastroenterol. 2013;48(5):633-5. doi: 10.3109/00365521.2013.775329Tursi A. Biomarkers in diverticular disease of the colon. Dig Dis. 2012;30(1):12-8. doi: 10.1159/000335695Schoepfer A.M, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin and blood leukocytes. Inflamm Bowel Dis. 2013;19(2):332-41. doi: 10.1097/MIB.0b013e3182810066Ricanek P, Brackmann S, Perminow G, Lyckander L.G, et al. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers. Scand J Gastroenterol. 2011;46(9):1081-91. doi: 10.3109/00365521.2011.584897Roseth A, Kristensen V, Malmstrom G.H, Skar V, Moum B. Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra - individual variability and standardisation of sampling procedure. Scand J Gastroenterol. 2016;51(5):548-55. doi: 10.3109/00365521.2015.1117650De Vos M, Louis E.J, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inlamm Bowel Dis. 2013;19(10):2111-7. doi: 10.1097/MIB.0b013e31829b2a37Sauter B, Beglinger C, Girardin M, et al. Monitoring disease activity and progression in Crohn's disease. A Swiss perspective on the IBD ahead 'optimised monitoring' recommendations. Digestion. 2014;89(4):299-309. doi: 10.1159/000360283Naismith G.D, Smith L.A, Barry S.J, et al. A prospective single - centre evaluation of the intra - individual variability of faecal calprotectin in quiescent Crohn's disease. Aliment Pharmacol Ther. 2013;37(6):613-21. doi: 10.1111/apt.12221Lasson A, Stotzer P.O, Ohman L, Isaksson S, Sapnara M, Strid H. The intra - individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis. 2015;9(1):26-32. doi: 10.1016/j.crohnsCalafat M, Cabre E, Manosa M, Lobaton T, Marin L, Domenech E. High within - day variability of fecal calprotectin levels in patients with active ulcerative colitis: What is the best timing for stool sampling? Inflamm Bowel Dis. 2015;21(5):1072-6. doi: 10.1097/MIB.0000000000000349Aguas M, Bastida G, Cerrillo E, Beltran B, Iborra M, Sanchez-Montes C, et al. Adalimumab in prevention of postoperative recurrence of Crohn's disease in high - risk patients. World J Gastroenterol. 2012;18(32):4391-8. doi: 10.3748/wjg.v18.i32.4391Yamamoto T. The clinical value of faecal calprotectin and lactoferrin measurement in postoperative Crohn's disease. Unit Eur Gastroenterol J. 2015;3(1):5-10. doi: 10.1177/2050640614558106Abraham B.P, Kane S. Fecal markers: calprotectin and lactoferrin. Gastroenterol Clin North Am. 2012;41(2):483-95. doi: 10.1016/j.gtc.2012.01.007Menees S.B, Powell C, Kurlander J, Goel A, Chey W.D. A meta - analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110(3):444-54. doi: 10.1038/ajg.2015.6Buderus S, Scholz D, Behrens R, et al. Inflammatory bowel disease in pediatric patients: Characteristics of newly diagnosed patients from the CEDATA-GPGE Registry. Dtsch Arztebl Int. 2015;112(8):121-7. doi: 10.3238/arztebl.2015.0121Mosli M.H, Zou G, Garg S.K, et al. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2015;110(6):802-19. doi: 10.1038/ajg.2015.120